ERAS (US) share price forecast & AI signal — Erasca, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in ERAS
Erasca, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with moderate confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Erasca, Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $14.41 |
| 2026-11-05 | $13.27 |
| 2026-11-04 | $14.91 |
| 2026-11-03 | $14.64 |
| 2026-11-02 | $14.05 |
| 2026-10-30 | $14.35 |
| 2026-10-29 | $14.98 |
ERAS FAQ
Is Erasca, Inc (ERAS) a buy or sell this week?
The ACE Stock Bots machine-learning model rates ERAS a BUY for the week of 2026-10-30 with moderate confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for ERAS?
Every week the model scores ERAS across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.